S. Marsoni

A. Rossi, F. de Marinis, M. Tiseo, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

R. Plummer, J. Verweij, J. Schellens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies

R. Herrmann, C. Sessa, S. Marsoni, 2011, Acta oncologica.

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

M. Zucchetti, F. D. De Braud, C. Sessa, 2009, European journal of cancer.

TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.

R. Labianca, I. Floriani, S. Marsoni, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

F. D. De Braud, G. Curigliano, C. Sessa, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.

R. Labianca, V. Torri, S. Marsoni, 2004, Journal of the National Cancer Institute.

Patterns of Care and Survival in Non Small Cell Lung Cancer: 15 Years’ Experience in a General Hospital

G. Luporini, V. Torri, M. Clerici, 1994, Tumori.

Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials

R. Labianca, D. Sargent, V. Torri, 2008 .

Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators.

S. Marsoni, 2001, Seminars in oncology.

Adjuvant Chemotherapy for Colon Cancer: Italian Studies

S. Marsoni, W. Torri, 1997, Tumori.

Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators

J. P. Pignon, Valter Torri, R. Labianca, 1995, The Lancet.

P31 Salvaging clinical trials forced to terminate early by results of external information

V. Torri, J. Pignon, S. Marsoni, 1993 .

Amsacrine-associated cardiotoxicity: an analysis of 82 cases.

S. Marsoni, R. Weiss, J. G. Posada, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators.

M. Indelli, V. Torri, A. Liberati, 1994, JAMA.

Therapeutic response in phase I trials of antineoplastic agents.

R. Wittes, B. Leyland-Jones, R. Simon, 1986, Cancer treatment reports.

DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials.

R. Labianca, D. Sargent, N. Foster, 2010 .

Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study.

R. Plummer, J. Verweij, J. Schellens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Process and outcome of care for patients with ovarian cancer.

A. Liberati, R. Talamini, F. Parazzini, 1985, British medical journal.

Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.

S. Marsoni, J. Macdonald, D. Poster, 1982, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

V. Torri, A. Bardelli, A. Sapino, 2022, Nature Medicine.

Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival.

F. Landoni, S. Marsoni, A. Codegoni, 1988, Cancer research.

Clinical development of anticancer agents--a National Cancer Institute perspective.

R. Wittes, S. Marsoni, 1984, Cancer treatment reports.

Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer.

S. Marsoni, A. Sartore-Bianchi, S. Siena, 2018, JAMA oncology.

Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC).

A. Bardelli, R. Yaeger, S. Kopetz, 2021 .

507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer

F. Ciardiello, A. Ardizzoni, S. Marsoni, 2020 .

Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of the National Cancer Institute.

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

R. Plummer, J. Verweij, J. Schellens, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.

V. Torri, A. Bardelli, F. Ciardiello, 2015 .

Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases

Alberto Torresin, Silvia Ghezzi, Francesco Rizzetto, 2020, European Radiology Experimental.

Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial

V. Torri, A. Bardelli, A. Sapino, 2019, Annals of Oncology.

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.

V. Torri, A. Bardelli, A. Sapino, 2021 .

Breaking Barriers in HER2+ Cancers.

S. Marsoni, A. Sartore-Bianchi, S. Siena, 2020, Cancer cell.

D01*Final Results of the HERACLES trial in HER2 amplified colorectal cancer

A. Bardelli, F. Ciardiello, L. Trusolino, 2016 .

Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib.

F. Ciardiello, S. Marsoni, M. Aglietta, 2020, JAMA oncology.

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer

S. Nik-Zainal, A. Bardelli, A. Degasperi, 2022, Clinical Cancer Research.

Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer

A. Bardelli, F. Ciardiello, L. Trusolino, 2017 .

Early ovarian cancer and the icon trials.

M. Parmar, L. Stewart, D. Ghersi, 1992, European journal of cancer.

Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?

B. Leyland-Jones, R. Simon, S. Marsoni, 1986, Cancer treatment reports.

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.

C. Sessa, S. Marsoni, L. Gianni, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors analysis in clinical oncology: handle with care.

M. Valsecchi, S. Marsoni, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.

S. Marsoni, M. Broggini, L. Morasca, 1980, Cancer treatment reports.

Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.

V. Torri, M. Clerici, M. Mandalà, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer Drug Development in Europe: A Selection of New Agents Under Development at the European Drug Development Network

D. Lacombe, P. Therasse, J. Verweij, 2003, Cancer Investigation.

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer.

S. Marsoni, A. Sartore-Bianchi, S. Siena, 2019, JAMA oncology.

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients

A. Bardelli, S. Marsoni, F. Di Nicolantonio, 2022, Cancer discovery.

VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma

S. Marsoni, L. Morasca, R. Scapaticci, 2004, Cancer Chemotherapy and Pharmacology.

Tolerance to antineoplastic agents in children and adults.

R. Simon, S. Marsoni, R. Ungerleider, 1985, Cancer treatment reports.

Monitoring clonal evolution and resistance to EGFR blockade in the blood of metastatic colorectal cancer patients

F. Nicolantonio, A. Bardelli, E. Medico, 2016 .

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

V. Torri, A. Bardelli, A. Sapino, 2020, ESMO Open.

HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.

A. Bardelli, F. Ciardiello, S. Marsoni, 2016 .

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.

G. Grasselli, I. Marimón, C. Sessa, 2006, European journal of cancer.

Etoposide (VP-16-213). Current status of an active anticancer drug.

R. Wittes, B. Leyland-Jones, S. Marsoni, 1985, The New England journal of medicine.

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver.

N. Segata, F. Asnicar, S. Marsoni, 2021, Cancer cell.

Precision oncology in metastatic colorectal cancer — from biology to medicine

R. Bernards, A. Bardelli, J. Tabernero, 2021, Nature Reviews Clinical Oncology.

The phase II trial.

S Marsoni, R Simon, R E Wittes, 1985, Cancer treatment reports.

How liquid biopsies can change clinical practice in oncology.

A. Bardelli, S. Kopetz, J. Seoane, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Flow cytometric analysis of DNA content in human ovarian cancers.

F. Landoni, S. Marsoni, P. Ubezio, 1989, British Journal of Cancer.

Tiazofurin: A new antitumor agent

S. Marsoni, P. O'dwyer, J. Plowman, 2004, Investigational new drugs.

2'-Deoxycoformycin: Summary and future directions

R. Wittes, S. Marsoni, P. O'dwyer, 1984 .

Personalized therapeutic strategies in HER2-driven gastric cancer

A. Sapino, S. Bellomo, P. Cassoni, 2021, Gastric Cancer.

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients

A. Bardelli, S. Marsoni, F. Di Nicolantonio, 2019, ESMO Open.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Davide Corà, Claudio Isella, Enzo Medico, 2011, Cancer discovery.

A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.

A. Bardelli, C. Isella, E. Medico, 2019, Clinical colorectal cancer.

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

A. Bardelli, C. Isella, E. Medico, 2019, Clinical Cancer Research.

Early‐onset colorectal cancer in young individuals

A. Bardelli, S. Marsoni, A. Russo, 2018, Molecular oncology.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

R. Labianca, D. Sargent, S. Thibodeau, 2011, Journal of the National Cancer Institute.

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

R. Labianca, V. Torri, S. Marsoni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

R. Labianca, M. Rugge, G. Viale, 2015, Modern Pathology.

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance

A. Bardelli, S. Marsoni, F. Di Nicolantonio, 2022, Cancer cell.

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

F. Rojo, J. Albanell, F. Haluska, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits.

A. Bass, A. Thorner, A. Sapino, 2019, Cancer research.

Amyloid aggregates accumulate in melanoma metastasis driving YAP mediated tumor progression

S. Marsoni, F. Casagrande, A. Bachi, 2020, bioRxiv.

An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

D. Katsaros, A. Gadducci, C. Sessa, 2012, International Journal of Gynecologic Cancer.

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

G. Giaccone, R. Labianca, V. Torri, 2013, The Lancet. Oncology.

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer.

N. Rosen, A. Bardelli, Y. Murciano-Goroff, 2020, Cancer discovery.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

V. Torri, A. Bardelli, F. Ciardiello, 2016, The Lancet. Oncology.

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.

M. Zucchetti, J. Baselga, C. Sessa, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas

V. Miller, A. Sapino, B. Alexander, 2021, Clinical Cancer Research.

A work in progress: The clinical development of histone deacetylase inhibitor

S. Marsoni, G. Damia, G. Camboni, 2008, Epigenetics.

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer

A. Bardelli, S. Marsoni, A. Sartore-Bianchi, 2022, British Journal of Cancer.

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.

R. Labianca, V. Torri, A. Bardelli, 2020 .

How liquid biopsies can change clinical practice in oncology.

A. Bardelli, S. Kopetz, J. Seoane, 2019 .

Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.

F. Nicolantonio, A. Bardelli, A. Santoro, 2019, Journal of Clinical Oncology.

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.

V. Torri, A. Bardelli, F. Ciardiello, 2019, The oncologist.

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

A. Bardelli, F. Penault-Llorca, S. McCall, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

C. Sessa, S. Marsoni, M. Voi, 2004, European journal of cancer.

Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

S. Serrano, F. Rojo, J. Albanell, 2010, Clinical Cancer Research.

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort

S Marsoni, M. Simone, A. Sapino, 2017, Oncogene.

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

V. Torri, A. Bardelli, M. Colombo, 2018, Clinical Cancer Research.

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

I. Floriani, S. Marsoni, M. Garassino, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases

A. Bardelli, S. Marsoni, A. Sartore-Bianchi, 2022, Cancers.

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib

A. Bardelli, S. Marsoni, F. Di Nicolantonio, 2019, Front. Oncol..

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case

A. Bardelli, N. Normanno, F. Ciardiello, 2018, ESMO Open.

Amyloid aggregates accumulate in melanoma metastasis modulating YAP activity

S. Marsoni, F. Casagrande, A. Bachi, 2020, EMBO reports.

Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.

V. Torri, M. Amichetti, S. Marsoni, 2003, International journal of radiation oncology, biology, physics.

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

M. Zucchetti, C. Sessa, S. Marsoni, 2010, European journal of cancer.

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.

M. Zucchetti, G. Grasselli, C. Sessa, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Teniposide: a review of 12 years of experience.

B. Leyland-Jones, S. Marsoni, P. O'dwyer, 1984, Cancer treatment reports.

Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate.

S. Marsoni, A. Trabattoni, L. Morasca, 1981, European journal of cancer.

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

F. Nicolantonio, A. Bardelli, E. Medico, 2015, Nature Medicine.

VP16 plasma levels after i.v. and two methods of oral administration to choriocarcinoma patients

S. Marsoni, M. D’Incalci, M. Fasoli, 1981 .

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.

A. Bardelli, S. Marsoni, G. Siravegna, 2019, Cancer treatment reviews.

Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.

V. Torri, S. Marsoni, N. Colombo, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

K. Broich, S. Marsoni, H. Zwierzina, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study

A. Bardelli, S. Marsoni, K. Bencardino, 2022, Cancers.

Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features.

A. Bardelli, A. Sapino, S. Marsoni, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Cancer in Transgender and Gender-Diverse Persons: A Review.

N. Scout, M. Schabath, R. Miceli, 2023, JAMA oncology.

Association of severe and fatal infections and treatment with pentostatin.

S. Marsoni, P. O'dwyer, A. Spiers, 1986, Cancer treatment reports.

Fluorouracil and folinic acid in colon cancer

S. Marsoni, L. Hughes-Davies, J. Rescigno, 1995, The Lancet.

Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids

A. Bardelli, S. Marsoni, A. Sartore-Bianchi, 2021, JCO precision oncology.

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial

R. Labianca, G. Apolone, H. Rauschecker, 1998, The Lancet.

Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.

V. Torri, F. Nicolantonio, A. Bardelli, 2018 .

The impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer.

V Torri, S Marsoni, P Zola, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.

N. Tomita, T. Yamanaka, N. Wolmark, 2021, Journal of the National Cancer Institute.

Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy

F. Grosso, P. Casali, S. Marsoni, 2007 .

Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).

M. Rugge, A. Bardelli, F. Ciardiello, 2013 .

An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-1) in patients with solid tumors.

C. Sessa, S. Marsoni, A. Fasolo, 2006, Journal of Clinical Oncology.

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

D. Lacombe, J. Verweij, J. Schellens, 2012, British Journal of Cancer.

Abstract A089: Exploiting clonal evolution and liquid biopsy to overcome resistance to anti-EGFR treatment in metastatic colorectal cancer: the CHRONOS trial

A. Bardelli, A. Santoro, A. Ardizzoni, 2018 .

Regulation of apoptosis

L. Pleyer, R. Greil, I. Tinhofer, 2007 .

Trends in Patterns of Care for Breast Cancer in Italy (1979-1987)

V. Torri, A. Liberati, G. Apolone, 1990, Tumori.

Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.

S. Marsoni, N. Colombo, C. Mangioni, 1991, Cancer treatment reviews.

Critical review of the quality and development of randomized clinical trials (RCTs) and their influence on the treatment of advanced epithelial ovarian cancer.

F. Parazzini, S. Marsoni, M. Franzosi, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.

S. Marsoni, J. Macdonald, J. Penta, 1980, Cancer clinical trials.

Cardiac events in phase II trials with mitoxantrone

S. Marsoni, C. Bergemann, L. Lev, 1984 .

420 Conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus conventional radiotherapy and concomitant chemotherapy in advanced oropharyngeal carcinoma: A randomized clinical trial

V. Torri, S. Marsoni, C. Fallai, 1995 .

Deacetylase inhibitor (DACI) panobinostat in relapsed small cell lung cancer (SCLC) patients: Results of a multicenter phase II trial.

C. Gridelli, M. Tiseo, S. Marsoni, 2010 .

First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.

M. Zucchetti, F. D. De Braud, M. Bellomi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, semantic and chemotherapy in advanced NSCLC.

M. Clerici, S. Marsoni, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology

R. Miceli, S. Marsoni, M. Lambertini, 2023, ESMO open.

Phase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine (CAPE).

J. Albanell, S. Marsoni, L. Gianni, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study with antifibronectin I-131 L19-SIP: First dosimetric and therapeutic results

S. Marsoni, L. Gianni, L. Zardi, 2007 .

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

D. Alberts, W. Sauerbrei, M. Buyse, 1998, British Journal of Cancer.

Treatment of advanced ovarian cancer (OC): A randomized trial comparing different platinum (P) combinations

C. Belloni, S. Marsoni, N. Colombo, 1986 .

Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC).

S. Barni, V. Torri, M. Ando, 2015 .

Abstract CT263: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: The PEGASUS trial

R. Labianca, V. Torri, M. Fassan, 2020 .

Erratum: DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy (Journal of the National Cancer Institute (2011) 103:11 (863-875))

R. Labianca, D. Sargent, S. Thibodeau, 2011 .

Bleomycin, vincristine, and methotrexate (BOM) in squamous cell carcinoma of the lung: a phase II study.

S. Marsoni, L. Morasca, A. Libretti, 1981, Cancer treatment reports.

Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.

A. Bardelli, F. Ciardiello, L. Trusolino, 2015 .

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

I. Floriani, S. Marsoni, M. Garassino, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical development of namitecan (ST1968), a novel camptothecin derivative with high antitumor activity: Phase I clinical data.

C. Sessa, S. Marsoni, A. Delmonte, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

F. Nicolantonio, A. Bardelli, S. Marsoni, 2017, Nature.

Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.

A. Bardelli, L. Trusolino, A. Bertotti, 2018, Cancer cell.

The Impact of Patient Management Guidelines on the Care of Breast, Colorectal, and Ovarian Cancer Patients in Italy

A. Liberati, G. Apolone, P. Zola, 1991, Medical care.

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

F. Rojo, J. Albanell, F. Haluska, 2010, Journal of Clinical Oncology.